Cargando…

Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers

SIMPLE SUMMARY: There have been few reports with regard to the relevance between the SARC-F score and the prognosis in patients with gastrointestinal advanced cancers, and we aimed to elucidate these issues (n = 421, median age = 73 years). During the follow-up period, 145 patients (34.4%) died. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsui, Masahiro, Nishikawa, Hiroki, Goto, Masahiro, Asai, Akira, Ushiro, Kosuke, Ogura, Takeshi, Takeuchi, Toshihisa, Nakamura, Shiro, Kakimoto, Kazuki, Miyazaki, Takako, Fukunishi, Shinya, Ohama, Hideko, Yokohama, Keisuke, Yasuoka, Hidetaka, Higuchi, Kazuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749778/
https://www.ncbi.nlm.nih.gov/pubmed/35008175
http://dx.doi.org/10.3390/cancers14010010
_version_ 1784631311417212928
author Matsui, Masahiro
Nishikawa, Hiroki
Goto, Masahiro
Asai, Akira
Ushiro, Kosuke
Ogura, Takeshi
Takeuchi, Toshihisa
Nakamura, Shiro
Kakimoto, Kazuki
Miyazaki, Takako
Fukunishi, Shinya
Ohama, Hideko
Yokohama, Keisuke
Yasuoka, Hidetaka
Higuchi, Kazuhide
author_facet Matsui, Masahiro
Nishikawa, Hiroki
Goto, Masahiro
Asai, Akira
Ushiro, Kosuke
Ogura, Takeshi
Takeuchi, Toshihisa
Nakamura, Shiro
Kakimoto, Kazuki
Miyazaki, Takako
Fukunishi, Shinya
Ohama, Hideko
Yokohama, Keisuke
Yasuoka, Hidetaka
Higuchi, Kazuhide
author_sort Matsui, Masahiro
collection PubMed
description SIMPLE SUMMARY: There have been few reports with regard to the relevance between the SARC-F score and the prognosis in patients with gastrointestinal advanced cancers, and we aimed to elucidate these issues (n = 421, median age = 73 years). During the follow-up period, 145 patients (34.4%) died. The 1-year cumulative overall survival rate in patients with SARC-F ≥ 4 (recommended cutoff point, n = 103) and SARC-F < 4 (n = 318) was 33.9% and 61.6% (p < 0.0001). In the multivariate analysis for the overall survival, total lymphocyte count ≥ 1081/μL (p = 0.0014), the SARC-F score ≥ 4 (p = 0.0096), Glasgow prognostic score 1 (p = 0.0147) and 2 (p < 0.0001), ECOG-PS 2 (p < 0.0001), and 3 (p < 0.0001) and 4 (p < 0.0001) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and the best cutoff point of the SARC-F score was two. The SARC-F score appears to be useful in patients with gastrointestinal advanced malignancies. ABSTRACT: We sought to elucidate the prognostic impact of the SARC-F score among patients with gastrointestinal advanced malignancies (n = 421). A SARC-F score ≥ 4 was judged to have a strong suspicion for sarcopenia. In patients with ECOG-PS 4 (n = 43), 3 (n = 61), and 0–2 (n = 317), 42 (97.7%), 53 (86.9%) and 8 (2.5%) had the SARC-F score ≥ 4. During the follow-up period, 145 patients (34.4%) died. All deaths were cancer-related. The 1-year cumulative overall survival (OS) rate in patients with SARC-F ≥ 4 (n = 103) and SARC-F < 4 (n = 318) was 33.9% and 61.6% (p < 0.0001). In the multivariate analysis for the OS, total lymphocyte count ≥ 1081/μL (p = 0.0014), the SARC-F score ≥ 4 (p = 0.0096), Glasgow prognostic score (GPS) 1 (p = 0.0147, GPS 0 as a standard), GPS 2 (p < 0.0001, GPS 0 as a standard), ECOG-PS 2 (p < 0.0001, ECOG-PS 0 as a standard), ECOG-PS 3 (p < 0.0001, ECOG-PS 0 as a standard), and ECOG-PS 4 (p < 0.0001, ECOG-PS 0 as a standard) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and best cutoff point of the SARC-F score was two. In conclusion, the SARC-F score is useful in patients with gastrointestinal advanced malignancies.
format Online
Article
Text
id pubmed-8749778
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87497782022-01-12 Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers Matsui, Masahiro Nishikawa, Hiroki Goto, Masahiro Asai, Akira Ushiro, Kosuke Ogura, Takeshi Takeuchi, Toshihisa Nakamura, Shiro Kakimoto, Kazuki Miyazaki, Takako Fukunishi, Shinya Ohama, Hideko Yokohama, Keisuke Yasuoka, Hidetaka Higuchi, Kazuhide Cancers (Basel) Article SIMPLE SUMMARY: There have been few reports with regard to the relevance between the SARC-F score and the prognosis in patients with gastrointestinal advanced cancers, and we aimed to elucidate these issues (n = 421, median age = 73 years). During the follow-up period, 145 patients (34.4%) died. The 1-year cumulative overall survival rate in patients with SARC-F ≥ 4 (recommended cutoff point, n = 103) and SARC-F < 4 (n = 318) was 33.9% and 61.6% (p < 0.0001). In the multivariate analysis for the overall survival, total lymphocyte count ≥ 1081/μL (p = 0.0014), the SARC-F score ≥ 4 (p = 0.0096), Glasgow prognostic score 1 (p = 0.0147) and 2 (p < 0.0001), ECOG-PS 2 (p < 0.0001), and 3 (p < 0.0001) and 4 (p < 0.0001) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and the best cutoff point of the SARC-F score was two. The SARC-F score appears to be useful in patients with gastrointestinal advanced malignancies. ABSTRACT: We sought to elucidate the prognostic impact of the SARC-F score among patients with gastrointestinal advanced malignancies (n = 421). A SARC-F score ≥ 4 was judged to have a strong suspicion for sarcopenia. In patients with ECOG-PS 4 (n = 43), 3 (n = 61), and 0–2 (n = 317), 42 (97.7%), 53 (86.9%) and 8 (2.5%) had the SARC-F score ≥ 4. During the follow-up period, 145 patients (34.4%) died. All deaths were cancer-related. The 1-year cumulative overall survival (OS) rate in patients with SARC-F ≥ 4 (n = 103) and SARC-F < 4 (n = 318) was 33.9% and 61.6% (p < 0.0001). In the multivariate analysis for the OS, total lymphocyte count ≥ 1081/μL (p = 0.0014), the SARC-F score ≥ 4 (p = 0.0096), Glasgow prognostic score (GPS) 1 (p = 0.0147, GPS 0 as a standard), GPS 2 (p < 0.0001, GPS 0 as a standard), ECOG-PS 2 (p < 0.0001, ECOG-PS 0 as a standard), ECOG-PS 3 (p < 0.0001, ECOG-PS 0 as a standard), and ECOG-PS 4 (p < 0.0001, ECOG-PS 0 as a standard) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and best cutoff point of the SARC-F score was two. In conclusion, the SARC-F score is useful in patients with gastrointestinal advanced malignancies. MDPI 2021-12-21 /pmc/articles/PMC8749778/ /pubmed/35008175 http://dx.doi.org/10.3390/cancers14010010 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Matsui, Masahiro
Nishikawa, Hiroki
Goto, Masahiro
Asai, Akira
Ushiro, Kosuke
Ogura, Takeshi
Takeuchi, Toshihisa
Nakamura, Shiro
Kakimoto, Kazuki
Miyazaki, Takako
Fukunishi, Shinya
Ohama, Hideko
Yokohama, Keisuke
Yasuoka, Hidetaka
Higuchi, Kazuhide
Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers
title Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers
title_full Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers
title_fullStr Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers
title_full_unstemmed Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers
title_short Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers
title_sort prognostic impact of the sarc-f score in gastrointestinal advanced cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749778/
https://www.ncbi.nlm.nih.gov/pubmed/35008175
http://dx.doi.org/10.3390/cancers14010010
work_keys_str_mv AT matsuimasahiro prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT nishikawahiroki prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT gotomasahiro prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT asaiakira prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT ushirokosuke prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT oguratakeshi prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT takeuchitoshihisa prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT nakamurashiro prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT kakimotokazuki prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT miyazakitakako prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT fukunishishinya prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT ohamahideko prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT yokohamakeisuke prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT yasuokahidetaka prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers
AT higuchikazuhide prognosticimpactofthesarcfscoreingastrointestinaladvancedcancers